Endothelial Dysfunction, Biomarkers, and Lung Function -Ancillary to MESA (MESA-LUNG)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00843271|
Recruitment Status : Unknown
Verified January 2012 by Columbia University.
Recruitment status was: Active, not recruiting
First Posted : February 13, 2009
Last Update Posted : January 16, 2012
|Condition or disease|
|Chronic Obstructive Pulmonary Disease (COPD) Emphysema Endothelial Dysfunction|
Chronic obstructive pulmonary disease (COPD) is currently the fourth leading cause of death in the United States, and morbidity and mortality from COPD continue to rise. Despite the magnitude of the problem, therapeutic options are limited - particularly in comparison to cardiovascular disease. Smoking cessation is essential to the treatment and prevention of COPD. However, although smoking is the principal cause of COPD, only a minority of smokers develops symptomatic COPD and many former smokers develop COPD years to decades after they have stopped smoking. The only other medical intervention proven to reduce mortality from COPD is supplemental oxygen therapy. There is therefore an urgent need for newer understandings of the pathophysiology of COPD that might lead to the development of better therapies for COPD.
MESA-Lung is ancillary of the ongoing Multi-Ethnic Study of Atherosclerosis (MESA). MESA-lung will utilize the various existing measures of endothelial function that have been already been collected in MESA (flow-mediated dilatation [FMD] and related biomarkers and gene polymorphisms) to test the hypotheses that the endothelial dysfunction occurs in the clinical COPD.
|Study Type :||Observational|
|Actual Enrollment :||4359 participants|
|Official Title:||Endothelial Dysfunction, Biomarkers, and Lung Function (MESA LUNG)|
|Study Start Date :||October 2004|
|Estimated Primary Completion Date :||November 2012|
|Estimated Study Completion Date :||November 2012|
MESA-Lung is an ancillary study of the Multi-Ethnic Study of Atherosclerosis (MESA). MESA, established in 1999, is well characterized, multi-ethnic (white, Black, Hispanic and Chinese), and multi-center (Columbia, Johns Hopkins, Northwestern, UCLA, Minnesota,and Wake Forest) prospective cohort study. MESA-Lung included a 60% random sample of the MESA cohort at the six Field Centers in Exam 3 and Exam 4, stratified on race/ethnicity.
- Lung Function [ Time Frame: 2004-2011 ]
- Lung Density [ Time Frame: 2000-2011 ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00843271
|Principal Investigator:||R. Graham Barr, M.D., Dr.PH.||Columbia University|